Every portfolio company from acquisition through value creation to exit.
| Company | Industry | Entry | Stage | Hold | Entry value |
|---|---|---|---|---|---|
| Freenom Growth Investment | Healthcare | 2026 | Value creation | 0.1y | $240M |
| Natera Minority Investment | Diagnostics | 2026 | Value creation | 0.2y | $602M |
| Revolution Medicines Minority Investment | Biopharmaceutical | 2026 | Value creation | 0.2y | $2.5B |
| Electronic Arts Minority Investment | — | 2026 | Value creation | 0.2y | $1.6B |
| BridgeBio Pharma Minority Investment | Biotechnology | 2026 | Value creation | 0.2y | $800M |
| GRAIL Minority Investment | Healthcare | 2026 | Value creation | 0.2y | — |
| Tango Therapeutics Minority Investment | Biotechnology | 2026 | Value creation | 0.2y | — |
| Protagonist Therapeutics Minority Investment | Biopharmaceutical | 2026 | Value creation | 0.2y | $778M |
| Amazon Minority Investment | — | 2026 | Value creation | 0.2y | $628M |
| Exelixis Minority Investment | Biopharmaceutical | 2026 | Value creation | 0.2y | $733M |
| Liquidia Minority Investment | Pharmaceutical | 2026 | Value creation | 0.2y | $667M |
| Lantheus Holdings Minority Investment | Diagnostic Imaging | 2026 | Value creation | 0.2y | $619M |
| UnitedHealth Group Minority Investment | — | 2026 | Value creation | 0.2y | $528M |
| Boston Scientific Minority Investment | — | 2026 | Value creation | 0.2y | $500M |
| Microsoft Corp. Minority Investment | — | 2026 | Value creation | 0.2y | — |
| Centessa Pharmaceuticals Minority Investment | Biotechnology | 2026 | Value creation | 0.2y | — |
| InfixRx Growth Investment | Healthcare | 2026 | Value creation | 0.3y | $150M |
| Saginet Biosciences Growth Investment | Healthcare | 2026 | Value creation | 0.4y | $175M |
| Mirador Therapeutics Growth Investment | Therapeutics | 2026 | Value creation | 0.7y | $250M |
| GRAIL Growth Investment | Healthcare | 2025 | Value creation | 0.9y | $325M |
| Pentera Growth Investment | Cybersecurity | 2025 | Value creation | 1.5y | $60M |